<DOC>
	<DOCNO>NCT02499562</DOCNO>
	<brief_summary>To explore effective dose safety effect hydronidone entecavir hepatic fibrosis chronic viral hepatitis B .</brief_summary>
	<brief_title>A Phase II Clinical Trial Hydronidone Capsules ( F351 ) Patients With Liver Fibrosis Induced HBV Chronic Hepatitis</brief_title>
	<detailed_description>Primary observation index : Hepatic fibrosis Ishak score treatment decrease proportion le 1 compare treatment . Secondary observation index : 1 . Negative conversion ratio HBV DNA treatment ( HBV DNA＜1×103copies/mL ) fall range . 2 . The fall proportion Fibrocan Kpa value treatment compare treatment . 3 . The fall proportion decrease less 1 level progression-free fibrosis treatment compare treatment . 4 . The improvement ALT liver function .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1 . Aged 1865 , gender . 2 . History chronic hepatitis B , HBsAg positive≧six month . 3 . ALT＜fivefold ULN ( maximum ) . 4 . Significant liver fibrosis confirm liver biopsy . 5 . HBeAg positive patient , HBV DNA＞2.0×104 IU/mL ( copies/mL ) ; HBeAg negative patients，HBV DNA＞2.0×103 IU/mL ( 104copies/mL ) . 6 . Having accept antiviral therapy interferon and/or nucleoside analog . 7 . Having take antiinflammatory drug protect liver within 1 month selection . 8 . Capable understand signing informed consent study . 1 . Failing meet one requirement inclusion criterion . 2 . Having suffer massive hemorrhage gastrointestinal tract within 3 month selection 3 . TBiL＞threefold ULN . 4 . AFP＞50 ug/L 5 . PLT≦60000ug/L 6 . Having obvious spaceoccupying lesion liver show B ultrasound examination . 7 . With portal vein ≧1.2cm wide show B ultrasound examination . 8 . BMI index＞30 . 9 . The patient suffer liver function decompensation hepatic cirrhosis liver neoplasms . 10 . The patient alcoholic , druginduced , hereditary , immune viral non viral chronic hepatitis . 11 . The patient angiocarpy , lung , kidney , incretion , nerve blood system disease mental disease . 12 . The patient active peptic ulcer . 13 . Gestational breast feed woman . 14 . The subject legal disable person accord Law People 's Republic China Protection Disabled Persons April 2008 edition . 15 . The subject participate drug test within recent 3 month . 16 . The patient suspect poor compliance disagrees participate test . 17 . The patient consider investigator suitable participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>